ARCA biopharma to Present at the Q4 Virtual Investor Summit on November 17th
10 November 2021 - 08:15AM
ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company
applying a precision medicine approach to developing genetically
targeted therapies for cardiovascular diseases, today announced
that Tom Keuer, Chief Operating Officer, will present at the Q4
Virtual Investor Summit being held November 16-17, 2021.
ARCA is scheduled to present on Wednesday, November
17, 2021 at 4:15 PM ET. Management will be available for one-on-one
meetings to be held throughout the conference. The presentation
will be webcast live and available for replay at:
https://us06web.zoom.us/webinar/register/WN_f2a6CQ14RLSGAC5STDNKrg.
About ARCA biopharmaARCA
biopharma is dedicated to developing genetically targeted therapies
for cardiovascular diseases through a precision medicine approach
to drug development. ARCA is developing rNAPc2 as a potential
treatment for COVID-19. The U.S. FDA has granted Fast Track
designation to the rNAPc2 development program, currently in Phase
2b clinical testing. ARCA is also developing
Gencaro™ (bucindolol hydrochloride), an investigational,
pharmacologically unique beta-blocker and mild vasodilator, as a
potential treatment for atrial fibrillation in heart failure
patients. ARCA has identified common genetic variations that it
believes predict individual patient response to Gencaro, giving it
the potential to be the first genetically targeted AF prevention
treatment. The U.S. FDA has granted the Gencaro development program
Fast Track designation and a Special Protocol Assessment (SPA)
agreement. For more information, please visit www.arcabio.com or
follow the Company on LinkedIn.
Investor & Media
Contact:Derek Cole720.940.2163derek.cole@arcabio.com
ARCA Biopharma (NASDAQ:ABIO)
Historical Stock Chart
From Feb 2024 to Mar 2024
ARCA Biopharma (NASDAQ:ABIO)
Historical Stock Chart
From Mar 2023 to Mar 2024